Author: Huette, Pierre; Abou Arab, Osama; Jounieaux, Vincent; Guilbart, Mathieu; Belhout, Mohamed; Haye, Guillaume; Dupont, Hervé; Beyls, Christophe; Mahjoub, Yazine
Title: Almitrine for COVID-19 critically ill patients – a vascular therapy for a pulmonary vascular disease: Three case reports Cord-id: 8053dncu Document date: 2021_5_16
ID: 8053dncu
Snippet: BACKGROUND: Several reports with clinical, histological and imaging data have observed the involvement of lung vascular function to explain the severe hypoxemia in coronavirus disease 2019 (COVID-19) patients. It has been hypothesized that an increased pulmonary blood flow associated with an impairment of hypoxic pulmonary vasoconstriction is responsible for an intrapulmonary shunt. COVID-19 may lead to refractory hypoxemia (PaO(2)/FiO(2 )ratio below 100 mmHg) despite mechanical ventilation and
Document: BACKGROUND: Several reports with clinical, histological and imaging data have observed the involvement of lung vascular function to explain the severe hypoxemia in coronavirus disease 2019 (COVID-19) patients. It has been hypothesized that an increased pulmonary blood flow associated with an impairment of hypoxic pulmonary vasoconstriction is responsible for an intrapulmonary shunt. COVID-19 may lead to refractory hypoxemia (PaO(2)/FiO(2 )ratio below 100 mmHg) despite mechanical ventilation and prone positioning. We hypothesized that the use of a pulmonary vasoconstrictor may help decrease the shunt and thus enhance oxygenation. CASE SUMMARY: We report our experience with three patients with refractory hypoxemia treated with almitrine to enhance oxygenation. Low dose almitrine (Vectarion(®); Servier, Suresnes, France) was started at an infusion rate of 4 μg × kg/min on a central line. The PaO(2)/FiO(2 )ratio and total respiratory system compliance during almitrine infusion were measured. For the three patients, the PaO(2)/FiO(2 )ratio time-course showed a dramatic increase whereas total respiratory system compliance was unchanged. The three patients were discharged from the intensive care unit. The intensive care unit length of stay for patient 1, patient 2 and patient 3 was 30 d, 32 d and 31 d, respectively. Weaning from mechanical ventilation was performed 13 d, 18 d and 15 d after almitrine infusion for patient 1, 2 and 3, respectively. We found no deleterious effects on the right ventricular function, which was similar to previous studies on almitrine safety. CONCLUSION: Almitrine may be effective and safe to enhance oxygenation in coronavirus disease 2019 patients. Further controlled studies are required.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and liver function test: 1, 2
- acute ards respiratory distress syndrome and longitudinal strain: 1, 2, 3, 4
- acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute ards respiratory distress syndrome and lopinavir ritonavir include: 1
- acute ards respiratory distress syndrome and lung compartment: 1
- acute ards respiratory distress syndrome and lung perfusion: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute ards respiratory distress syndrome and lung region: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and lung vascular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- acute ards respiratory distress syndrome and lung vascular function: 1
- acute respiratory syndrome and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- acute respiratory syndrome and liver function test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory syndrome and lobar involvement: 1, 2, 3
- acute respiratory syndrome and longitudinal annular displacement: 1
- acute respiratory syndrome and longitudinal annular displacement tricuspid: 1
- acute respiratory syndrome and longitudinal strain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory syndrome and lopinavir ritonavir include: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute respiratory syndrome and lung compartment: 1, 2, 3, 4, 5
- acute respiratory syndrome and lung opacity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Co phrase search for related documents, hyperlinks ordered by date